|
PGE-M Biomarker Bibliography
Altorki N. et al. Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 21, 2645-2650 (2003).
Csiki, I. et al. Targeting Cyclooxygenase-2 in Recurrent Non-Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel. Clinical Cancer Research 11, 6634-6640 (2005).
Edelman, M. et al. Eiconsanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy – Cancer and Leukemia Group B Trial 30203. Journal of Clinical Oncology 26, 848-855 (2008).
Fidler, M.J. et al. The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib. Clinical Cancer Research 14, 2088-2094 (2008).
Fujitia, T. et al. Size- and Invasion-Dependent Increase in Cyclooxygenase 2 Levels in Human Colorectal Carcinomas. Cancer Research 58, 4823-4826 (1998).
Grösch, S. et al. Cyclooxygenase-2 (COX-2)-Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. Journal of the National Cancer Institute 98, 736-747 (2006).
Huang, M. et al. Non-Small Cell Lung Cancer Cyclooxygenase-2-Dependent Regulation of Cytokine Balance in Lymphocytes and Macrophages: Up-Regulation of Interleukin 10 and Down-Regulation of Interleukin 12 Production. Cancer Research 58, 1208-1216 (1998).
Kutchera, W. et al. Protaglandin H Sythases 2 is Expressed Abnormally in Human Color Cancer: Evidence for a Transcriptional Effect. Proceeding of the National Academy of Sciences 93, 4816-4820 (1996).
Lippman S. et al. Combined Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways. Clinical Cancer Research 17, 6097-6099 (2005).
Masferrer, J. et al. Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors. Cancer Research 60, 1306-1311 (2000).
Murphey, L. et al. Quantification of the Major Urinary Metabolite of PGE2 by a Liquid Chromatographic/Mass Spectrometric Assay: Determination of Cyclooxygenase-Specific PGE2 Synthesis in Healthy Humans and those with Lung Cancer. Analytical Biochemistry 334, 266-275 (2004).
Reckamp, K. et al. A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research 12, 3381-3388, (2006).
Soslow, R. et al. COX-2 Is Expressed Human Pulmonary, Colonic, and Mammary Tumors. Cancer 89, 2637-2645 (2000).
Subbaramaiah, K. et al. Cyclooxygenase -2 Is Overexpress in HER-2/Neu-positive Breast Cancer. The Journal of Biological Chemistry 277, 18649-18657 (2002).
Thun M. et al. Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmcologic and Clinical Issues. Journal of the National Cancer Institute 94, 252-266 (2002).
Wolff, H. et al. Expression of Cyclooxygenase-2 in Human Lung Carcinoma. Cancer Research 58, 4997-5001 (1998).
| 
